Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLPCOV-01
- Development stage
- Unknown
- Lead developer
- VLP Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VLPCOV-01 is a self-amplifying messenger RNA (sa-mRNA) vaccine candidate developed by VLP Therapeutics Japan for the prevention of COVID-19. Unlike conventional mRNA vaccines, sa-mRNA vaccines incorporate a replicase gene, typically derived from alphaviruses, which allows the mRNA to replicate itself once inside the host cell. This mechanism results in higher and more sustained levels of antigen expression, potentially allowing for lower dosing requirements compared to standard mRNA platforms. VLPCOV-01 specifically encodes the SARS-CoV-2 spike protein and is delivered via intramuscular injection. The vaccine entered clinical development in Japan to evaluate its safety, tolerability, and immunogenicity in healthy adults.
- Other names
- VLPCOV-01 SARS-CoV-2 vaccineVLPCOV01 SARS-CoV-2 vaccineVLPCOV 01 SARS-CoV-2 vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)
Beyond the preview
Go deeper on VLPCOV-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLPCOV-01.